Funded Startups in Heidelberg
Disclosed funding in Heidelberg is dominated by a single outlier: Affimed’s $90M Post-IPO Equity round on 2022-04-13, which sits far above the next-largest…
Disclosed funding in Heidelberg is dominated by a single outlier: Affimed’s $90M Post-IPO Equity round on 2022-04-13, which sits far above the next-largest disclosed amounts in this slice (Getsafe’s $63M on 2021-10-06 and Exciva’s $59M on 2026-01-20). At the low end, the smallest disclosed amount is Musaic’s $100K Pre-Seed on 2021-02-15, while other smaller disclosed rounds cluster around $2M–$9M (e.g., Living Brain $2M on 2022-07-11; paretos $9M on 2024-10-28).
The 17 rows span 2021-02-15 through 2026-04-30, with multiple entries concentrated in the mid-2024 window (paretos 2024-10-28; become.1 2024-09-18; Enzo 2024-07-12; FundaMental Pharma 2024-04-11). Sector-wise, Biotechnology appears 3+ times (Exciva, Lillian Care, FundaMental Pharma, Living Brain, Affimed, Novaliq), and Stage mix includes several undisclosed amounts (3 entries: Lillian Care 2025-10-13; Unikraft 2023-03-23; Paicon 2022-11-22) plus one “Venture - Series Unknown” (Novaliq on 2022-04-12).
Most recent rounds
17 shownRelated listings
Frequently asked
Which disclosed round looks like an outlier in Heidelberg, and how does it compare to the rest of the disclosed figures shown?
Affimed’s $90M Post-IPO Equity on 2022-04-13 is the clear high outlier; it is notably above Getsafe’s $63M on 2021-10-06 and Exciva’s $59M on 2026-01-20, while many other disclosed amounts fall into the $2M–$27M range (e.g., Living Brain $2M on 2022-07-11; Aleph Alpha $27M on 2021-07-27).
Is there a concentration in time among these Heidelberg rounds rather than a flat distribution?
Yes. Several rounds cluster in 2024, including FundaMental Pharma on 2024-04-11 ($3M), Enzo on 2024-07-12 ($3M), become.1 on 2024-09-18 ($4M), and paretos on 2024-10-28 ($9M), before additional entries extend into late 2024 and into 2025–2026 (e.g., Unikraft $6M on 2025-10-10; Cirql One $6M on 2026-04-30).
Are any sectors over-represented in this Heidelberg list, and what does that imply about deal focus?
Biotechnology appears in 6 of the 17 rows (Exciva, Lillian Care, FundaMental Pharma, Living Brain, Affimed, Novaliq), which is much higher than sectors with single-digit counts like AI/Software/Apps. That concentration is reinforced by repeated multi-million disclosed rounds in biotech (e.g., Exciva $59M on 2026-01-20; Novaliq $15M on 2022-04-12; Living Brain $2M on 2022-07-11).
Which stage types dominate the disclosed activity here, accounting for undisclosed amounts?
Seed rounds are frequent across the list (e.g., Cirql One 2026-04-30 $6M; Unikraft 2025-10-10 $6M; Enzo 2024-07-12 $3M; Living Brain 2022-07-11 $2M), and at least three companies have undisclosed amounts (Lillian Care 2025-10-13; Unikraft 2023-03-23; Paicon 2022-11-22). Post-Seed/large-ticket visibility is comparatively concentrated in a few non-Seed entries such as Affimed’s $90M Post-IPO Equity (2022-04-13) and Getsafe’s $63M Series B (2021-10-06).
Are there any notable low-end or missing-disclosure signals that a diligence list should flag?
At the low end, Musaic’s $100K Pre-Seed on 2021-02-15 is far smaller than most other disclosed amounts in the table. Separately, undisclosed rounds appear 3 times (Lillian Care on 2025-10-13; Unikraft on 2023-03-23; Paicon on 2022-11-22), so any sizing analysis that relies only on disclosed values would miss part of the recent Heidelberg pipeline.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.